| 영문 | edema | 한글 | 부종 |
|---|---|---|---|
| 설명 | 조직내에 림프액이나 조직의 삼출물 등의 액체가 저류되어서 과잉 존재하는 상태를 말한다. 이런 현상은 생기는 부위에 따라 피하부종, 폐부종, 복수라 하며, 발생 기전에 따라 분류하면 울혈성 부종, 염증성 부종, 혈관운동성 부종, 기아성 부종, 콩팥탓 부종 등으로 분류된다. 울혈성 부종은 기능성 부종이라고도 하며, 정맥이나 림프관의 협착, 폐쇄로 인하여 정상적인 흐름이 방해받았을 때에 발생하는 것이다. 염증성 부종은 염증성 변화로 인해서 혈관의 투과성이 항진되어 혈관속에 있는 수분이 많이 조직으로 빠져 나가서 생기는 부종이고, 혈관운동성 부종은 혈관운동신경 마비로 유발되며, 기아성 부종은 만성적으로 영양이 부족한 경우에 생기는 부종이다. 콩팥탓 부종은 콩팥병이 있는 경우에 소변으로 영양분이 빠져나가는 경우에 유발된다. 부종은 생기는 부위에 따라 다소 차이가 있을지라도 발생기전에서는 서로 밀접한 관련을 맺고 있으므로 근본적인 원인을 찾아내어 치료를 시작하는 것이 바람직하다. |
||
| 영문 | pelvic inflammatory disease | 한글 | 골반염질환 |
|---|---|---|---|
| 설명 | 골반주위의 장기에 발생하는 염증을 말함. 주로 여성에서 발생하며 원인은 임균(gonococcus)과 비임균에 의한 감염(non-gonorrheal infection)에 의한다. 증상은 초기에는 질분비물, 하복부동통, 여성의 생식기부위에 발생하는 압통, 월경통, 월경량의 증가 등이다. 일찍 치료해야 하며, 계속적으로 병이 지속시 여성의 불임의 원인이 된다. 후진국에서는 가장 많은 여성불임의 원인이기도 함. 치료는 항생제의 투여이다. |
||
| 영문 | inflammatory bowel disease | 한글 | 염증성창자병 |
|---|---|---|---|
| 설명 | 위장관을 침범하는 정확한 원인이 밝혀지지 않은 만성적인 염증성 질환을 말한다. 크게 ‘궤양성 대장염’(ulcerative colitis)과 ‘크론병’(Crohn's disease)의 두 종류로 구분된다. 백인, 유태인에 많고 흑인이나 동양인에는 드물지만 동양인에서 점차 증가추세에 있다. 호발연령은 15~35세 사이이다. 증상은 ‘궤양성 대장염’의 경우, 설사(혈변 및 점액변), 뒤무직, 복통, 복부압통, 체중감소 등이 주로 나타나며 ‘크론병’에서는 설사와 체중감소, 우하복부 종류, 항문주위 이상, 복부압통 등이 나타난다. 진단은 병력과 방사선학적 검사, 직장경 및 대장 내시경검사, 직장 및 대장의 조직검사로 하며 치료는 내과적인 치료가 원칙이나 내과적 치료에 듣지 않거나 합병증이 생길 경우에는 외과적 치료를 시행한다. ‘궤양성 대장염’의 경우에는 ‘대장암’을 예방하기 위해서 외과적 치료를 하기도 한다. ‘궤양성 대장염’과 ‘크론 병’외에 염증성 창자병에 속하는 ‘베체트 병’은 재발성 구강내 궤양, 피부 병변, 안구부 염증, 외음부 궤양, 관절염 증상, 위창자관 증상(복통, 장출혈), 부고환염 등의 증상을 나타내는데 진단과 치료는 ‘궤양성 대장염’, ‘크론 병’과 비슷하다. |
||
| 영문 | anti-inflammatory agent | 한글 | 항염증제, 소염제, 염증약 |
|---|---|---|---|
| 설명 | 국소에 작용하여 염증을 치료하고 방지하는 약. 염증을 가라앉히는 약을 말한다. 조직을 긴축-치밀하게 하여 장액과 점액의 분비를 줄이고, 표면에 있는 작은 혈관에 빈혈을 일으켜 충혈되는 것을 방지함으로써 염증적 병변을 제거하여 모든 증세를 없앤다. 대부분의 수렴제-완화제-진양제가 이에 속한다. 중요한 성분으로는 알루미늄-비스무트-아연-납화합물(병반-페르마톨-아연화-연당 등) 등이 있다. 작용에 따라 항염증진통제와 항염증효소제로 나뉜다. |
||
| HPE | hepatic portoenterostomy; high-permeability edema; history and physical examination; holoprosencepha... |
|---|---|
| PAIN | pyoderma gangrenosum, aphthous stomatitis, inflammatory eye disease, erythema nodosum [disorders ass... |
| EF | Edema Factor |
| HACE | High Altitude Cerebral Edema |
| HAPE | High Altitude Pulmonary Edema |
| BE | Brain edema |
|---|---|
| CSME | Clinically significant macular edema |
| CME | Cystoid macular edema |
| EPH | Edema Proteinuria Hypertension |
| HANE | Hereditary Angio Neurotic Edema |
| edema | <clinical sign> The presence of abnormally large amounts of fluid in the intercellular tissue spaces of the body, usually applied to demonstrable accumulation of excessive fluid in the subcutaneous tissues. Oedema may be localised, due to venous or lymphatic obstruction or to increased vascular permeability or it may be systemic due to heart failure or renal disease. Collections of oedema fluid are designated according to the site, for example ascites (peritoneal cavity), hydrothorax (pleural cavity) and hydropericardium (pericardial sac). Massive generalised oedema is called anasarca. Origin: Gr. Oide ma = swelling (18 Nov 1997) |
|---|---|
| edema, cardiac | A manifestation of congestive heart failure caused by increased venous and capillary pressures and often associated with the retention of sodium by the kidneys. (12 Dec 1998) |
| acute inflammatory polyneuropathy | <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin. The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months. Synonym: Guillain-Barre syndrome (12 Jul 2000) |
| anti-inflammatory | Counteracting or suppressing inflammation. (18 Nov 1997) |
| anti-inflammatory agent | Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |
| anti-inflammatory agent, steroidal | Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents. (12 Dec 1998) |
| anti-inflammatory agent, topical | Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application. (12 Dec 1998) |
| macrophage inflammatory protein | <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other. They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells. They most likely also play a significant role in respiratory tract defenses. (20 Sep 2002) |
| pelvic inflammatory disease | <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections. (27 Sep 1997) |
| chronic inflammatory demyelinating polyneuropathy | An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone. (05 Mar 2000) |
| chronic inflammatory polyneuropathy | <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response. The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable. Origin: Gr. Pathos = disease (27 Sep 1997) |
| non-steroidal anti-inflammatory | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
| non-steroidal anti-inflammatory drug | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
| desquamative inflammatory vaginitis | An acute inflammation of the vagina of unknown cause, characterised by grayish pseudomembrane, free discharge, and easy bleeding on trauma; the discharge contains pus and immature epithelial cells, although oestrogen levels are normal. Vaginitis emphysematosa, vaginitis characterised by accumulation of gas in small connective tissue spaces lined by foreign-body giant cells. Synonym: pachyvaginitis cystica, vaginitis cystica. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|